Table 2.

Treatment‐emergent adverse events occurring with P218 at doses of 10‐1000 mg or placebo in Part A and following 250 mg P218 in fed or fasted state in Part B

Adverse event, n subjects (%)	Part A								Part B (250 mg P218)
	10 mg (n = 6)	30 mg (n = 6)	100 mg (n = 6)	250 mg (n = 6)	500 mg (n = 6)	750 mg (n = 6)	1000 mg (n = 6)	Placebo (n = 14)	Fasted (n = 8)	Fed (n = 8)
Any adverse events	0	0	2 (33.3)	1 (16.7)	2 (33.3)	3 (50.0)	3 (50.0)	3 (21.4)	0	1 (12.5)
Presyncope	0	0	0	0	1 (16.7)	0	0	0	0	0
Dizziness	0	0	0	0	0	0	0	0	0	1 (12.5)
Abdominal pain	0	0	0	0	0	0	2 (33.3)	0	0	0
Constipation	0	0	1 (16.7)	1 (16.7)	0	0	0	0	0	0
Faeces soft	0	0	0	0	0	0	1 (16.7)	0	0	0
Nausea	0	0	0	0	0	0	0	0	0	1 (12.5)
Nasopharyngitis	0	0	0	0	0	2 (33.3)	0	1 (7.1)	0	0
Sinusitis	0	0	1 (16.7)	0	0	0	0	0	0	0
Back pain	0	0	0	0	0	2 (33.3)	0	0	0	0
Headache	0	0	0	0	1 (16.7)	0	1 (16.7)	1 (7.1)	0	1 (12.5)
Paraesthesia	0	0	0	0	0	0	0	0	0	1 (12.5)
Oropharyngeal pain	0	0	0	0	0	0	1 (16.7)	1 (7.1)	0	0

All events were mild, except one case of moderate back pain (Part A: 750 mg).